Vericel Corp

VCEL · XNAS

CIK 887359fmd_1DJTMRQKTBJ24NEC847D1TJPFBManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard

Coverage: Jul 01, 2008 to Sep 30, 2026, 67 periods

Income Statement · Annual · Millions · USD
Line item	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Total revenues	54	64	91	118	124	156	164	198	237	276
Cost of revenue	28	30	32	38	40	50	55	62	65	71
Gross profit	26	34	59	80	84	106	110	136	172	206
Research and development	15	13	14	30	13	16	20	21	25	28
Selling, general and administrative	27	36	49	61	69	98	107	121	143	167
Total operating expenses	45	49	63	92	82	114	127	142	168	195
Operating income	(19)	(15)	(4)	(11)	2	(8)	(17)	(6)	5	11
Interest expense	0	0	0	0	0	0	0	1	1	1
Interest and investment income	0	0	1	2	1	0	1	5	6	7
Other non-operating income (expense)	(0)	(2)	(4)	2	1	0	1	4	6	6
Income before taxes	(20)	(17)	(8)	(10)	3	(8)	(16)	(2)	11	17
Income tax expense	0	0	0	0	0	(0)	1	1	0	1
Net income from continuing operations	(20)	(17)	(8)	(10)	3	(7)	(17)	(3)	10	17
Net income	(20)	(17)	(8)	(10)	3	(7)	(17)	(3)	10	17
Net income to common shareholders	(27)	(17)	(8)	–	–	–	–	–	–	–